2024-04-08 14:24:00
Sensorion raises 15 million euros
The Montpellier-based biotech Sensorion, specializing in the treatment of hearing disorders, has announced financing of 15 million euros, obtained by private placement with the issue of new shares. Investors include Sofinnova Partners and Redmile Group. With this financing, Sensorion is extending its cash flow horizon until the end of 2025. A few weeks ago, the biotech had already raised 50 million euros, “ which brings the total amount raised to 100 million euros in less than 9 months », welcomed Nawal Ouzren, CEO of Sensorion. The biotech wants in particular to use these funds to advance its two gene therapies, Sens-501 in its phase I/II clinical study and also progress on its second program, GJB2-GT, with the submission of clinical trial applications hoped for in first half of 2025. In a press release, Sensorion also specifies that it “ continues to seek non-dilutive financing ».
I will tell you
source
Fresenius Kabi launches Tyenne, the first tocilizumab biosimilar in France
Fresenius Kabi launched the first tocilizumab biosimilar in France, called Tyenne, after obtaining authorization from the European Commission on February 1 for around ten European countries. Until then and since 2009, the monoclonal antibody was marketed in Europe by the Roche laboratory under the name Actemra/RoActemra. Tocilizumab, which acts by blocking pro-inflammatory cytokines, has been approved to treat rheumatoid arthritis and, by extrapolation, all indications of the reference drug: giant cell arteritis, juvenile idiopathic arthritis, release syndrome. cytokines as well as certain serious forms of Covid-19.
Pierluigi Antonelli, CEO of Fresenius Kabi, was pleased to have arrived at the head of the race to offer a biosimilar of tocilizumab to the European market: “ We are very proud to be the first company to offer an affordable, high-quality, safe tocilizumab treatment option for healthcare professionals and patients with inflammatory and autoimmune diseases », he rejoiced. But this is not the only market in which the drug has been launched. On March 7, Tyenne also obtained approval from the FDA for its marketing in the United States, just a few months after the launch by Biogen of the first tocilizumab biosilimaire authorized on American soil, Tofidence. After acquiring Merck KGaA’s biosimilar portfolio in 2017, Fresenius Kabi would like to continue on this path by developing other treatments, particularly in the fields of oncology and autoimmune diseases. The German group, which achieved a turnover of 26.4 billion euros in 2023, has already launched two other biosimilars named Idacio and Stimufend.
MSD acquires American biotech Abceutics
The Merck laboratory, known as MSD outside the United States and Canada, has just acquired an American start-up called Abceutics and launched in 2020. The agreement allows the American giant to take control on biotech-developed molecules designed to improve the safety and efficacy of antibody-drug conjugates (ADCs), a new class of cancer drugs consisting of a monoclonal antibody coupled to a cytotoxic payload via a linker. The Abceutics team has developed “ payload link selectivity amplifiers » (PBSE) to bind and neutralize parasitic payload molecules. “ PBSEs are intended to be administered with ADCs to reduce the risk of side effects, thereby potentially optimizing selective therapy and ADC treatment efficacy said Joseph P. Balthasar, co-founder of Abceutics. The amount of the agreement could reach up to $208 million, split between an upfront payment and conditional payments depending on the success of their drug candidates.
Novo Nordisk files a new authorization request from the American authorities regarding the operation with Catalent
After announcing last February that it wanted to take over the American subcontractor Catalent to increase the production of its flagship drug, Wegovy, Novo Nordisk submitted a first request for approval on March 4. While the $16.5 billion deal was under study, the Danish laboratory decided to file a new request for approval on April 2 with the US Federal Trade Commission (FTC). ). This decision following “ informal discussions with FTC staff ”, according to a Catalent filing dated April 3 and filed with the SEC, the American stock market regulator. Novo Nordisk had announced the final conclusion of the agreement for the end of 2024. For the moment, no information concerning whether or not this date will be maintained, or the precise reasons leading to the filing of this new request, has been disclosed.
Selected for you
1712682785
#Sensorion #Fresenius #Kabi #MSD #Novo #Nordic